~~<i id='1999868EE0'><strike id='1999868EE0'><tt id='1999868EE0'><pre id='1999868EE0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

author：focus 2025-09-28 04:42:34 - browse：6

Calling Bullshit course University of Washington — Screenshot via callingbullshit.org

Tired of alternative facts, fake news, and breathless hyperbole, two professors at the University of Washington are trying to strike a blow for science.

Their weapon? A new course: “Calling Bullshit In the Age of Big Data.”

The class website and colorful syllabus went online last month and almost instantly went viral.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： BIO to announce reorganization, senior leaders expected to depart

hotspot

entertainment

hotspot

entertainment

Wikipedia

hotspot

MattRourke/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsle

WSS

Crowdfunding for medical bills sidesteps core problem, author says

CDC concerned about possible undetected monkeypox spread in U.K.

Gene therapy has helped boys walk. Can scientists keep it that way?

The strategy behind pharma's lawsuits over drug pricing reform

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Why we need to separate burnout from moral injury in health care

knowledge

knowledge

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

AltruBio raises $225 million to develop ulcerative colitis drug

23andMe had bad news about my health. I wish a person had delivered it

Crowdfunding for medical bills sidesteps core problem, author says

Moonlake's readout produced a cash windfall. Risks remain

AI for drug discovery: Experts on separating hype from reality

Virginia high school admissions case could be legal follow

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Apple is now the first public company to be valued at $3 trillion

PBM executives asked to testify by House panel

entertainment

With FDA staff opposed to Sarepta therapy, top official intervened

Crowdfunding for medical bills sidesteps core problem, author says

Death of patient in Alzheimer’s trial raises question of possible risks

Brain technologies pose threats that are all too real, experts warn

Chemotherapy before breast cancer surgery might fuel metastasis

As health system earnings go up, health insurance stocks go down

hotspot

entertainment

Wikipedia

hotspot